Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Arrowhead Therapeutics

- PMLiVE

Amgen’s Imdelltra granted FDA accelerated approval to treat small cell lung cancer

More than 234,000 new cases of lung cancer are expected to be diagnosed in the US this year

- PMLiVE

Novo Nordisk to acquire cardiovascular disease specialist Cardior in deal worth over €1bn

The deal includes a candidate being evaluated in a mid-stage trial to treat heart failure patients

- PMLiVE

Sandoz receives FDA approval for first denosumab biosimilars Wyost and Jubbonti

The biosimilars have been authorised for all indications covered by Amgen's reference medicines

- PMLiVE

UK Biobank reveals new data from world’s largest genetic project

The data will accelerate the development of potentially lifesaving treatments and cures

- PMLiVE

New blood test to reduce heart attacks and death rates in A&E heart patients

The test could improve diagnosis for one in five patients with a heart muscle injury

- PMLiVE

Risk calculator to prevent heart attacks and strokes in type 2 diabetes patients

About one-third of adults living with diabetes die from a heart or circulatory disease

- PMLiVE

Amgen’s Wezlana receives FDA approval to treat multiple inflammatory diseases

Wezlana is approved as a biosimilar referencing Janssen Pharmaceuticals’ Stelara

- PMLiVE

Amgen presents new findings for Uplizna in neuromyelitis optica spectrum disorder

The rare and debilitating disease affects approximately one to ten per 100,000 people

- PMLiVE

EDX Medical Group develops multi-disease ‘point-of-care’ rapid tests for cancer, infections and cardiovascular conditions

The development follows the Group’s acquisition of Hutano Diagnostics

- PMLiVE

Amgen free to proceed with $27.8bn Horizon acquisition following US FTC settlement

The FTC filed an antitrust lawsuit against Amgen earlier this year in a bid to block the transaction

- PMLiVE

Alliance for Genomic Discovery announces its five founding biopharma members

The AGD aims to accelerate drug development and expand the diversity of genomic data

- PMLiVE

Amgen’s supplemental Biologics License Application for Blincyto approved by FDA

The approval for the leukaemia drug was supported by additional data from two phase 3 studies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links